

## SUPPLEMENTARY PROSPECTUS DATED 29 APRIL 2022



### **NatWest Markets Plc**

*(Incorporated in Scotland with limited liability under the Companies Acts 1948 to 1980,  
registered number SC090312)*

**£15,000,000,000**

**Euro Medium Term Note Programme**

**US\$10,000,000,000**

**US Medium Term Note Programme**

This supplement (the "**Supplementary Prospectus**") to (i) the prospectus dated 7 December 2021 relating to the £15,000,000,000 Euro Medium Term Note Programme established by NatWest Markets Plc (the "**Issuer**" or "**NatWest Markets**") (as supplemented, the "**EMTN Prospectus**") and (ii) the base prospectus dated 16 March 2022 relating to the US\$10,000,000,000 US Medium Term Note Programme established by the Issuer (the "**USMTN Prospectus**" and, together with the EMTN Prospectus, the "**Prospectuses**" and each a "**Prospectus**"), each of which comprises a base prospectus for the purpose of Regulation (EU) 2017/1129, as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the "**UK Prospectus Regulation**"), constitutes a supplementary prospectus for the purposes of Article 23 of the UK Prospectus Regulation.

Terms defined in each Prospectus have the same meaning when used in this Supplementary Prospectus.

This Supplementary Prospectus constitutes the 3<sup>rd</sup> Supplementary Prospectus in respect of the EMTN Prospectus and the 1<sup>st</sup> Supplementary Prospectus in respect of the USMTN Prospectus.

This Supplementary Prospectus is supplemental to, and should be read in conjunction with, each Prospectus and the documents incorporated by reference therein.

This Supplementary Prospectus has been approved by the United Kingdom Financial Conduct Authority (the "**FCA**"), as competent authority under the UK Prospectus Regulation. The FCA only approves this Supplementary Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the UK Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer that is the subject of this Supplementary Prospectus. With effect from the date of this Supplementary Prospectus the information appearing in, or incorporated by reference into, the Prospectus shall be supplemented in the manner described below.

The Issuer accepts responsibility for the information contained in this Supplementary Prospectus. To the best of the knowledge of the Issuer such information is in accordance with the facts and makes no omission likely to affect its import.

### **Purpose of the Supplementary Prospectus**

The purpose of this Supplementary Prospectus is to:

- (a) incorporate by reference into each Prospectus the NatWest Markets Q1 2022 IMS (as defined below);
- (b) following publication of the NatWest Markets Q1 2022 IMS, update the statement of no significant change;
- (c) update certain information in relation to legal proceedings; and
- (d) update the capitalisation table in respect of the USMTN Prospectus.

### **Incorporation of Information by Reference**

By virtue of this Supplementary Prospectus the unaudited Q1 2022 Interim Management Statement of the Issuer (the "**NatWest Markets Q1 2022 IMS**"), which was published via the regulatory news service of the London Stock Exchange plc on 29 April 2022, and which has been (1) previously published and (2) filed with the Financial Conduct Authority, shall be incorporated in, and form part of each Prospectus.

For at least ten years from the date of each Prospectus, a copy of any or all of the information which is incorporated by reference in the Prospectuses can be obtained from the website of NatWest Group plc at [investors.natwestgroup.com/regulatory-news/company-announcements](https://investors.natwestgroup.com/regulatory-news/company-announcements) and from the London Stock Exchange plc's website at [www.londonstockexchange.com/news](https://www.londonstockexchange.com/news).

If a document which is incorporated by reference in the Prospectuses by virtue of this Supplementary Prospectus itself incorporates any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of the Prospectuses except where such information or other documents are specifically incorporated by reference in, or attached to, each Prospectus by virtue of this Supplementary Prospectus.

It should be noted that, except as set forth above, no other portion of the above documents is incorporated by reference into the Prospectuses. In addition, where sections of any of the above documents which are incorporated by reference into the Prospectuses cross-reference other sections of the same document, such cross-referenced information shall not form part of the Prospectuses, unless otherwise incorporated by reference herein. Those parts of the documents incorporated by reference which are not specifically incorporated by reference in this Supplementary Prospectus are either not relevant for prospective investors or the information is included elsewhere in the Prospectuses.

### **Statement of No Significant Change**

There has been no significant change in the financial position or financial performance of the NWM Group taken as a whole since 31 March 2022 (the end of the last financial period for which the latest interim financial information of the NWM Group has been published).

## Updating the legal proceedings disclosure set out in the Prospectus

The section entitled "*Legal Proceedings*" on page 73 of the EMTN Prospectus shall be deleted and replaced with the following:

### "Legal Proceedings

For a description of the material governmental, legal or arbitration proceedings that NatWest Markets and the NWM Group face, see (i) the section entitled "*Litigation and regulatory matters*" in the "*Notes*" at page 11 of the NatWest Markets Q1 2022 IMS and (ii) the section entitled "*Legal and Arbitration Proceedings*" at pages 117 to 124 of the Registration Document, each as referred to in, and incorporated by reference into, this Prospectus."

### Legal Proceedings

Other than as referred to in (i) the section entitled "*Litigation and regulatory matters*" in the "*Notes*" at page 11 of the NatWest Markets Q1 2022 IMS as referred to in, and incorporated by reference into the Prospectus and (ii) the section entitled "*Legal and Arbitration Proceedings*" at pages 117 to 124 of the Registration Document, there are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Issuer is aware), which may have or have had during the 12 months preceding the date of this Supplementary Prospectus, a significant effect on the financial position or profitability of NatWest Markets and/or the NWM Group.

## Updating the capitalisation disclosure set out in the USMTN Prospectus

The section entitled "*Capitalisation*" on page 35 of the USMTN Prospectus shall be deleted and replaced with the following:

"

### CAPITALISATION

The following table sets forth, as at 31 March 2022, the Issuer's consolidated capitalisation and indebtedness:

	<b>As at 31 March 2022</b>
	<u>£m</u>
Bank deposits – amortised cost (including repos) .....	2,005
Customer deposits – amortised cost .....	3,458
Trading liabilities excluding short positions.....	45,896
<i>of which: repo</i> .....	26,405
<i>of which: debt securities in issue</i> .....	883
<i>of which: other deposits</i> .....	1,465
<i>of which: derivative cash collateral received</i> .....	17,143
Other financial liabilities .....	20,042
<i>of which: customer deposits – designated fair value</i> .....	565
<i>of which: debt securities in issue</i> .....	18,577
<i>of which: subordinated liabilities</i> .....	900
Amounts due to holding company and fellow subsidiaries .....	5,214
<i>of which: internal MREL instruments issued to NatWest Group plc</i> .	2,880

<i>of which: other bank and customer deposits</i> .....	897
<i>of which: subordinated liabilities</i> .....	1,437
<b>Total senior funding and subordinated liabilities</b> .....	76,615
<b>Total owner's equity</b> .....	7,086
Non-controlling interests .....	-3
Total equity .....	7,083
<b>Total senior funding, subordinated liabilities and equity</b> .....	<b>83,698</b>

The table above should be read in conjunction with the financial statements incorporated by reference into this Base Prospectus.

The Issuer regularly considers various market funding options and accesses the debt capital markets in a variety of issuance formats, currencies and tenors from time to time in connection with executing its funding plans."

### **Other Information**

To the extent that there is any inconsistency between any statement in this Supplementary Prospectus and any other statement in or incorporated by reference in each Prospectus, the statements in this Supplementary Prospectus will prevail.

Save as disclosed in this Supplementary Prospectus no other significant new factor, material mistake or material inaccuracy relating to information included in each Prospectus has arisen or been noted, as the case may be, since the publication of the Prospectus.

The hyperlinks included in this Supplementary Prospectus are included for information purposes only and the websites and their content are not incorporated into, and do not form part of, this Supplementary Prospectus or the Prospectuses.